Pulmatrix, Inc.

Healthcare · Biotechnology · United States

Last price 1.4 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.11M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in ch...